Ascendis Pharma A/S (ASND) News

Ascendis Pharma A/S (ASND): $104.18

-3.48 (-3.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ASND to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter ASND News Items

ASND News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ASND News Highlights

  • ASND's 30 day story count now stands at 9.
  • Over the past 23 days, the trend for ASND's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • MSCI, AIM and ALX are the most mentioned tickers in articles about ASND.

Latest ASND News From Around the Web

Below are the latest news stories about Ascendis Pharma A that investors may wish to consider to help them evaluate ASND as an investment opportunity.

Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conference Call on March 2

COPENHAGEN, Denmark, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will hold a conference call and live webcast on Wednesday, March 2, 2022 at 4:30 p.m. Eastern Time (ET) to review its 2021 financial results and provide a business update. Conference Call Details DateWednesday, March 2, 2022Time4:30 p.m. Eastern Time/1:30 p.m. Pacific TimeDial In (U.S.)844-290-3904Dial In (International)574-990-1036Access Code2009938 A live webcast of the co

Yahoo | February 25, 2022

Artisan Partners ‘Remains Quite Optimistic’ in Ascendis Pharma (ASND)

Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded here. A return of -0.72% was recorded by its Investor Class: ARTMX, -0.68% by its Advisor Class: APDMX, and -0.66% by its Institutional Class: APHMX, in the fourth […]

Yahoo | February 25, 2022

Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight

Las Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist...

Benzinga | February 21, 2022

Ascendis Pharma A/S to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

COPENHAGEN, Denmark, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the 11th Annual SVB Leerink Global Healthcare Conference. Company executives will participate in a virtual fireside chat hosted by SVB Leerink.

GlobeNewswire | February 10, 2022

CIBC Asset Management Inc Buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, ...

Toronto, A6, based Investment company CIBC Asset Management Inc (Current Portfolio) buys Bank of Nova Scotia, Franco-Nevada Corp, Suncor Energy Inc, NVIDIA Corp, iShares MSCI EAFE ETF, sells Shaw Communications Inc, Progressive Corp, Visa Inc, Allegion PLC, Lightspeed Commerce Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, CIBC Asset Management Inc.

Yahoo | February 8, 2022

Ascendis Pharma's (NASDAQ:ASND) investors will be pleased with their incredible 399% return over the last five years

It hasn't been the best quarter for Ascendis Pharma A/S ( NASDAQ:ASND ) shareholders, since the share price has fallen...

Yahoo | February 8, 2022

Capital Asset Advisory Services LLC Buys iShares Russell 3000 ETF, iShares 7-10 Year Treasury ...

Investment company Capital Asset Advisory Services LLC (Current Portfolio) buys iShares Russell 3000 ETF, iShares 7-10 Year Treasury Bond ETF, Vanguard Short-Term Inflation-Protected Securities, Vanguard Ultra-Short Bond ETF, iShares Short Treasury Bond ETF, sells Vanguard Total Bond Market ETF, iShares iBoxx USD High Yield Corporate Bond ETF, SPDR Dow Jones Industrial Average ETF, Utilities Select Sector SPDR ETF, SPDR MSCI USA StrategicFactors SM ETF during the 3-months ended 2021Q4, according

Yahoo | February 4, 2022

HC Advisors, LLC Buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, ...

Investment company HC Advisors, LLC (Current Portfolio) buys Vanguard Short-Term Government Bond ETF, Apellis Pharmaceuticals Inc, Amgen Inc, Dyne Therapeutics Inc, UnitedHealth Group Inc, sells Netflix Inc, Invesco S&P 500 Equal Weight ETF, PIMCO Energy & Tactical Credit Opportunities, Pinduoduo Inc, Alphabet Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HC Advisors, LLC.

Yahoo | February 2, 2022

Ascendis Pharma AS (ASND) Surges 6.5%: Is This an Indication of Further Gains?

Ascendis Pharma AS (ASND) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Yahoo | January 25, 2022

Ascendis Pharma (ASND) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

No summary available.

Seeking Alpha | January 24, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5763 seconds.